Free Trial

Treace Medical Concepts (TMCI) Financials

Treace Medical Concepts logo
$6.65 +0.24 (+3.76%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Treace Medical Concepts

Annual Income Statements for Treace Medical Concepts

This table shows Treace Medical Concepts' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-43 -49 -56
Consolidated Net Income / (Loss)
-43 -50 -56
Net Income / (Loss) Continuing Operations
-43 -50 -56
Total Pre-Tax Income
-43 -50 -56
Total Operating Income
-35 -51 -56
Total Gross Profit
116 152 168
Total Revenue
142 187 209
Operating Revenue
142 187 209
Total Cost of Revenue
26 35 41
Operating Cost of Revenue
26 35 41
Total Operating Expenses
151 203 224
Selling, General & Admin Expense
33 47 56
Marketing Expense
105 141 148
Research & Development Expense
14 15 21
Other Operating Expenses / (Income)
- -0.34 -0.32
Total Other Income / (Expense), net
-7.97 1.90 -0.50
Interest Expense
8.88 5.17 5.26
Interest & Investment Income
1.31 6.73 4.88
Other Income / (Expense), net
-0.40 - -0.12
Basic Earnings per Share
($0.77) ($0.81) ($0.90)
Weighted Average Basic Shares Outstanding
55.28M 60.85M 62.11M
Diluted Earnings per Share
($0.77) ($0.81) ($0.90)
Weighted Average Diluted Shares Outstanding
55.28M 60.85M 62.11M
Weighted Average Basic & Diluted Shares Outstanding
61.16M 61.76M 62.62M

Quarterly Income Statements for Treace Medical Concepts

This table shows Treace Medical Concepts' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-12 -8.11 -13 -12 -17 -5.97 -19 -21 -15 -0.50
Consolidated Net Income / (Loss)
-12 -4.41 -13 -12 -18 -6.28 -19 -21 -15 -0.50
Net Income / (Loss) Continuing Operations
-12 -8.13 -13 -12 -18 -6.51 -19 -21 -15 -1.01
Total Pre-Tax Income
-12 -8.13 -13 -12 -18 -6.51 -19 -21 -15 -1.01
Total Operating Income
-11 -3.50 -14 -13 -18 -6.78 -19 -21 -15 -0.20
Total Gross Profit
27 41 34 34 33 51 41 36 36 55
Total Revenue
33 50 42 42 41 62 51 44 45 69
Operating Revenue
33 50 42 42 41 62 51 44 45 69
Total Cost of Revenue
6.09 9.02 8.04 7.68 8.00 11 10 8.78 8.95 13
Operating Cost of Revenue
6.09 9.02 8.04 7.68 8.00 11 10 8.78 8.95 13
Total Operating Expenses
38 44 48 47 51 57 60 57 51 56
Selling, General & Admin Expense
8.92 10 11 10 13 13 14 14 14 14
Marketing Expense
26 30 34 34 34 40 40 38 33 37
Research & Development Expense
3.80 3.75 3.41 3.53 4.35 4.15 5.26 5.16 4.96 5.21
Other Operating Expenses / (Income)
0.05 - - -0.10 -0.02 - -0.07 -0.11 -0.02 -0.12
Total Other Income / (Expense), net
-0.82 -4.58 0.32 0.78 0.30 0.50 0.42 0.15 -0.26 -0.81
Interest Expense
1.19 10 1.29 1.28 1.30 1.30 1.32 1.31 1.31 1.31
Interest & Investment Income
0.42 0.75 1.48 1.97 1.57 1.71 1.54 1.38 1.07 0.90
Other Income / (Expense), net
- - 0.13 - - - 0.20 0.08 -0.01 -0.39
Basic Earnings per Share
($0.22) ($0.08) ($0.23) ($0.20) ($0.28) ($0.10) ($0.30) ($0.34) ($0.25) ($0.01)
Weighted Average Basic Shares Outstanding
55.43M 55.28M 58.72M 61.38M 61.56M 60.85M 61.79M 62.08M 62.23M 62.11M
Diluted Earnings per Share
($0.22) ($0.08) ($0.23) ($0.20) ($0.28) ($0.10) ($0.30) ($0.34) ($0.25) ($0.01)
Weighted Average Diluted Shares Outstanding
55.43M 55.28M 58.72M 61.38M 61.56M 60.85M 61.79M 62.08M 62.23M 62.11M
Weighted Average Basic & Diluted Shares Outstanding
55.50M 61.16M 61.33M 61.54M 61.68M 61.76M 62.01M 62.19M 62.30M 62.62M

Annual Cash Flow Statements for Treace Medical Concepts

This table details how cash moves in and out of Treace Medical Concepts' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-86 -6.49 -1.63
Net Cash From Operating Activities
-31 -35 -37
Net Cash From Continuing Operating Activities
-31 -35 -37
Net Income / (Loss) Continuing Operations
-43 -50 -56
Consolidated Net Income / (Loss)
-43 -50 -56
Depreciation Expense
2.13 5.35 8.42
Amortization Expense
0.12 -1.11 -0.85
Non-Cash Adjustments To Reconcile Net Income
16 20 34
Changes in Operating Assets and Liabilities, net
-5.81 -9.74 -23
Net Cash From Investing Activities
-77 -81 35
Net Cash From Continuing Investing Activities
-77 -81 35
Purchase of Property, Plant & Equipment
-15 -11 -12
Acquisitions
0.00 -20 0.00
Purchase of Investments
-63 -170 -72
Sale and/or Maturity of Investments
1.73 120 119
Net Cash From Financing Activities
21 109 0.16
Net Cash From Continuing Financing Activities
21 109 0.16
Repayment of Debt
-0.99 0.00 0.00
Issuance of Debt
50 0.00 0.00
Issuance of Common Equity
0.00 108 0.00
Other Financing Activities, net
-28 1.86 0.16
Cash Interest Paid
4.40 5.17 4.96

Quarterly Cash Flow Statements for Treace Medical Concepts

This table details how cash moves in and out of Treace Medical Concepts' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-4.29 -69 10 -18 -4.76 5.70 -3.65 8.85 -6.07 -0.76
Net Cash From Operating Activities
-7.48 -5.36 -17 -8.34 -9.51 0.53 -7.22 -14 -12 -4.21
Net Cash From Continuing Operating Activities
1.51 -5.65 -17 -8.47 -9.51 0.53 -7.22 -14 -12 -4.21
Net Income / (Loss) Continuing Operations
-12 -4.41 -13 -12 -18 -6.28 -19 -21 -15 -0.50
Consolidated Net Income / (Loss)
-12 -4.41 -13 -12 -18 -6.28 -19 -21 -15 -0.50
Depreciation Expense
0.46 0.92 0.92 1.10 1.56 1.77 1.91 2.12 2.16 2.24
Amortization Expense
0.07 -0.05 -0.22 -0.29 -0.29 -0.30 -0.26 -0.28 -0.16 -0.15
Non-Cash Adjustments To Reconcile Net Income
12 3.98 4.04 4.66 4.88 6.86 8.25 8.16 8.81 8.75
Changes in Operating Assets and Liabilities, net
1.00 -6.09 -8.41 -1.67 1.85 -1.52 1.56 -2.69 -7.29 -15
Net Cash From Investing Activities
-5.86 -64 -80 -10 4.60 5.01 3.76 22 5.76 3.42
Net Cash From Continuing Investing Activities
-5.86 -64 -80 -10 4.60 5.01 3.76 22 5.76 3.42
Purchase of Property, Plant & Equipment
-5.86 -2.33 -1.48 -4.23 -3.50 -2.25 -3.93 -1.73 -2.86 -3.07
Purchase of Investments
- -63 -100 -21 -19 -30 -29 - -24 -19
Sale and/or Maturity of Investments
- 1.73 21 35 27 37 36 24 33 25
Net Cash From Financing Activities
0.35 0.30 108 1.18 0.16 0.17 -0.19 0.31 0.01 0.03
Net Cash From Continuing Financing Activities
0.35 0.30 108 1.18 0.16 0.17 -0.19 0.31 0.01 0.03
Other Financing Activities, net
0.35 -34 0.35 1.18 0.16 0.17 -0.19 0.31 0.01 0.03
Cash Interest Paid
1.19 1.31 1.29 1.28 1.30 1.30 1.32 1.17 1.24 1.22

Annual Balance Sheets for Treace Medical Concepts

This table presents Treace Medical Concepts' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
159 252 217
Total Current Assets
133 198 161
Cash & Equivalents
19 13 11
Short-Term Investments
62 110 64
Accounts Receivable
29 38 41
Inventories, net
19 29 39
Prepaid Expenses
3.62 7.85 5.67
Plant, Property, & Equipment, net
15 22 26
Total Noncurrent Assets
10 31 30
Goodwill
0.00 13 13
Intangible Assets
0.00 9.03 8.08
Other Noncurrent Operating Assets
10 9.41 8.85
Total Liabilities & Shareholders' Equity
159 252 217
Total Liabilities
98 114 104
Total Current Liabilities
30 45 35
Accounts Payable
8.67 12 11
Accrued Expenses
14 21 17
Current Employee Benefit Liabilities
7.67 7.55 6.58
Other Current Liabilities
0.34 4.43 0.51
Total Noncurrent Liabilities
68 69 69
Long-Term Debt
53 53 53
Other Noncurrent Operating Liabilities
16 16 16
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
61 138 113
Total Preferred & Common Equity
61 138 113
Preferred Stock
0.00 0.00 0.00
Total Common Equity
61 138 113
Common Stock
145 272 303
Retained Earnings
-85 -134 -190
Treasury Stock
0.00 -0.01 -0.28
Accumulated Other Comprehensive Income / (Loss)
-0.03 0.16 0.10

Quarterly Balance Sheets for Treace Medical Concepts

This table presents Treace Medical Concepts' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
156 249 250 240 243 226 213
Total Current Assets
128 223 198 187 187 172 158
Cash & Equivalents
89 30 12 7.28 9.33 18 12
Short-Term Investments
- 141 127 115 101 77 71
Accounts Receivable
19 25 27 25 30 26 24
Inventories, net
17 23 26 29 36 41 44
Prepaid Expenses
4.01 4.59 5.28 11 11 9.67 7.02
Plant, Property, & Equipment, net
14 16 19 22 25 24 25
Total Noncurrent Assets
14 10 32 32 31 30 30
Goodwill
- - 13 13 13 13 13
Intangible Assets
- - 9.50 9.26 8.79 8.55 8.31
Other Noncurrent Operating Assets
14 10 9.80 9.61 9.21 8.92 9.03
Total Liabilities & Shareholders' Equity
156 249 250 240 243 226 213
Total Liabilities
94 92 100 103 116 114 108
Total Current Liabilities
23 23 30 33 47 44 38
Accounts Payable
7.88 5.08 8.15 8.68 21 18 19
Accrued Expenses
9.32 14 13 14 21 20 13
Current Employee Benefit Liabilities
5.05 3.30 5.37 5.07 4.20 6.19 5.60
Other Current Liabilities
0.33 - 3.78 5.19 1.02 0.52 0.57
Total Noncurrent Liabilities
72 68 70 69 69 69 70
Long-Term Debt
53 53 53 53 53 53 53
Other Noncurrent Operating Liabilities
19 15 17 16 16 16 17
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
62 158 150 138 126 112 105
Total Preferred & Common Equity
62 158 150 138 126 112 105
Preferred Stock
0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity
62 158 150 138 126 112 105
Common Stock
143 256 261 266 279 287 294
Retained Earnings
-80 -98 -110 -128 -153 -174 -189
Treasury Stock
- - - - -0.25 -0.25 -0.25
Accumulated Other Comprehensive Income / (Loss)
- -0.06 -0.22 -0.15 0.07 -0.03 0.19

Annual Metrics and Ratios for Treace Medical Concepts

This table displays calculated financial ratios and metrics derived from Treace Medical Concepts' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
50.22% 31.92% 11.89%
EBITDA Growth
-110.85% -43.00% -2.23%
EBIT Growth
-113.49% -45.91% -8.52%
NOPAT Growth
-111.05% -47.60% -8.28%
Net Income Growth
-108.33% -15.68% -12.55%
EPS Growth
-79.07% -5.19% -11.11%
Operating Cash Flow Growth
-78.26% -12.81% -7.50%
Free Cash Flow Firm Growth
-174.53% -80.42% 13.94%
Invested Capital Growth
92.64% 111.79% 33.61%
Revenue Q/Q Growth
13.01% 7.12% 3.20%
EBITDA Q/Q Growth
6.37% -6.03% 12.79%
EBIT Q/Q Growth
4.59% -6.82% 10.37%
NOPAT Q/Q Growth
5.68% -6.82% 10.56%
Net Income Q/Q Growth
4.90% -3.92% 9.39%
EPS Q/Q Growth
7.23% -2.53% 9.09%
Operating Cash Flow Q/Q Growth
-5.53% 14.56% -14.61%
Free Cash Flow Firm Q/Q Growth
-13.91% 5.63% -22.79%
Invested Capital Q/Q Growth
21.67% -1.29% 20.15%
Profitability Metrics
- - -
Gross Margin
82.00% 81.20% 80.37%
EBITDA Margin
-23.26% -25.22% -23.04%
Operating Margin
-24.57% -27.48% -26.60%
EBIT Margin
-24.85% -27.48% -26.66%
Profit (Net Income) Margin
-30.19% -26.47% -26.63%
Tax Burden Percent
100.00% 99.31% 99.21%
Interest Burden Percent
121.47% 96.97% 100.68%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-100.39% -72.19% -49.26%
ROIC Less NNEP Spread (ROIC-NNEP)
-65.30% -44.79% -13.04%
Return on Net Nonoperating Assets (RNNOA)
44.64% 22.28% 4.81%
Return on Equity (ROE)
-55.75% -49.91% -44.45%
Cash Return on Invested Capital (CROIC)
-163.70% -143.90% -78.04%
Operating Return on Assets (OROA)
-23.51% -25.03% -23.80%
Return on Assets (ROA)
-28.56% -24.10% -23.77%
Return on Common Equity (ROCE)
-55.73% -49.91% -44.45%
Return on Equity Simple (ROE_SIMPLE)
-70.73% -35.91% -49.38%
Net Operating Profit after Tax (NOPAT)
-24 -36 -39
NOPAT Margin
-17.20% -19.24% -18.62%
Net Nonoperating Expense Percent (NNEP)
-35.09% -27.40% -36.22%
Return On Investment Capital (ROIC_SIMPLE)
-21.54% -18.85% -23.45%
Cost of Revenue to Revenue
18.00% 18.80% 19.63%
SG&A Expenses to Revenue
23.27% 25.13% 26.61%
R&D to Revenue
9.58% 8.25% 9.83%
Operating Expenses to Revenue
106.57% 108.50% 106.82%
Earnings before Interest and Taxes (EBIT)
-35 -51 -56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-33 -47 -48
Valuation Ratios
- - -
Price to Book Value (P/BV)
21.08 5.70 4.11
Price to Tangible Book Value (P/TBV)
21.08 6.77 5.04
Price to Revenue (P/Rev)
9.00 4.20 2.21
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
39.00 10.57 4.87
Enterprise Value to Revenue (EV/Rev)
8.79 3.83 2.11
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.87 0.38 0.47
Long-Term Debt to Equity
0.87 0.38 0.47
Financial Leverage
-0.68 -0.50 -0.37
Leverage Ratio
1.95 2.07 1.87
Compound Leverage Factor
2.37 2.01 1.88
Debt to Total Capital
46.55% 27.76% 32.07%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
46.55% 27.76% 32.07%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
53.45% 72.24% 67.93%
Debt to EBITDA
-1.60 -1.12 -1.11
Net Debt to EBITDA
0.87 1.49 0.46
Long-Term Debt to EBITDA
-1.60 -1.12 -1.11
Debt to NOPAT
-2.16 -1.47 -1.37
Net Debt to NOPAT
1.17 1.95 0.57
Long-Term Debt to NOPAT
-2.16 -1.47 -1.37
Altman Z-Score
7.97 4.19 2.26
Noncontrolling Interest Sharing Ratio
0.03% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
4.41 4.40 4.62
Quick Ratio
3.65 3.58 3.34
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-40 -72 -62
Operating Cash Flow to CapEx
-206.55% -301.75% -320.60%
Free Cash Flow to Firm to Interest Expense
-4.48 -13.89 -11.75
Operating Cash Flow to Interest Expense
-3.45 -6.69 -7.07
Operating Cash Flow Less CapEx to Interest Expense
-5.12 -8.91 -9.28
Efficiency Ratios
- - -
Asset Turnover
0.95 0.91 0.89
Accounts Receivable Turnover
5.94 5.56 5.31
Inventory Turnover
1.71 1.45 1.20
Fixed Asset Turnover
15.60 9.94 8.68
Accounts Payable Turnover
4.01 3.43 3.68
Days Sales Outstanding (DSO)
61.46 65.60 68.75
Days Inventory Outstanding (DIO)
213.66 251.98 304.22
Days Payable Outstanding (DPO)
90.95 106.36 99.29
Cash Conversion Cycle (CCC)
184.16 211.22 273.68
Capital & Investment Metrics
- - -
Invested Capital
32 68 91
Invested Capital Turnover
5.84 3.75 2.65
Increase / (Decrease) in Invested Capital
15 36 23
Enterprise Value (EV)
1,247 716 441
Market Capitalization
1,276 786 463
Book Value per Share
$1.09 $2.24 $1.81
Tangible Book Value per Share
$1.09 $1.88 $1.48
Total Capital
113 191 166
Total Debt
53 53 53
Total Long-Term Debt
53 53 53
Net Debt
-29 -70 -22
Capital Expenditures (CapEx)
15 11 12
Debt-free, Cash-free Net Working Capital (DFCFNWC)
22 30 51
Debt-free Net Working Capital (DFNWC)
103 153 126
Net Working Capital (NWC)
103 153 126
Net Nonoperating Expense (NNE)
18 14 17
Net Nonoperating Obligations (NNO)
-29 -70 -22
Total Depreciation and Amortization (D&A)
2.25 4.24 7.57
Debt-free, Cash-free Net Working Capital to Revenue
15.44% 16.10% 24.26%
Debt-free Net Working Capital to Revenue
72.73% 81.94% 60.41%
Net Working Capital to Revenue
72.73% 81.94% 60.41%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($0.77) ($0.81) ($0.90)
Adjusted Weighted Average Basic Shares Outstanding
55.28M 60.85M 62.11M
Adjusted Diluted Earnings per Share
($0.77) ($0.81) ($0.90)
Adjusted Weighted Average Diluted Shares Outstanding
55.28M 60.85M 62.11M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
61.16M 61.76M 62.62M
Normalized Net Operating Profit after Tax (NOPAT)
-24 -36 -39
Normalized NOPAT Margin
-17.20% -19.24% -18.62%
Pre Tax Income Margin
-30.19% -26.65% -26.84%
Debt Service Ratios
- - -
EBIT to Interest Expense
-3.97 -9.95 -10.62
NOPAT to Interest Expense
-2.75 -6.97 -7.42
EBIT Less CapEx to Interest Expense
-5.64 -12.17 -12.82
NOPAT Less CapEx to Interest Expense
-4.42 -9.18 -9.62
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Treace Medical Concepts

This table displays calculated financial ratios and metrics derived from Treace Medical Concepts' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
52.90% 48.84% 45.26% 40.00% 23.30% 25.00% 21.12% 5.96% 10.62% 10.44%
EBITDA Growth
-106.37% 50.15% -67.77% 26.92% -53.43% -101.98% -32.24% -58.88% 20.56% 128.04%
EBIT Growth
-107.29% 37.52% -68.58% 24.27% -57.43% -93.94% -37.53% -63.20% 15.01% 91.23%
NOPAT Growth
-107.29% 37.52% -70.16% -9.38% -57.43% -93.94% -37.69% -63.82% 15.06% 96.99%
Net Income Growth
-89.05% 33.34% -48.89% 28.80% -44.41% -42.36% -38.81% -72.81% 12.33% 92.02%
EPS Growth
-83.33% 42.86% -43.75% 35.48% -27.27% -25.00% -30.43% -70.00% 10.71% 90.00%
Operating Cash Flow Growth
19.23% -42.80% -138.35% 21.11% -27.13% 109.93% 58.16% -66.73% -24.48% -890.79%
Free Cash Flow Firm Growth
19.37% -160.35% -195.06% -168.44% -222.83% -127.18% -28.30% 56.01% 68.44% 43.43%
Invested Capital Growth
52.54% 92.64% 129.91% 178.52% 161.04% 111.79% 70.27% 10.91% 9.77% 33.61%
Revenue Q/Q Growth
10.30% 50.56% -15.22% -0.57% -2.85% 52.64% -17.85% -13.02% 1.42% 52.39%
EBITDA Q/Q Growth
35.65% 75.61% -392.09% 5.39% -35.09% 67.89% -222.19% -13.67% 32.45% 111.34%
EBIT Q/Q Growth
34.33% 69.10% -290.28% 4.37% -36.52% 61.94% -176.76% -13.48% 28.91% 96.07%
NOPAT Q/Q Growth
5.15% 69.10% -293.94% 5.26% -36.52% 61.94% -179.68% -12.73% 29.22% 98.65%
Net Income Q/Q Growth
29.60% 63.64% -204.94% 8.79% -42.78% 64.15% -197.34% -13.55% 27.57% 96.74%
EPS Q/Q Growth
29.03% 63.64% -187.50% 13.04% -40.00% 64.29% -200.00% -13.33% 26.47% 96.00%
Operating Cash Flow Q/Q Growth
29.18% 28.40% -222.12% 51.71% -14.13% 105.59% -1,457.33% -92.45% 14.79% 64.47%
Free Cash Flow Firm Q/Q Growth
8.36% -5.02% -83.37% -52.11% -10.21% 26.10% -3.56% 47.84% 20.93% -32.46%
Invested Capital Q/Q Growth
15.61% 21.67% 27.54% 55.25% 8.36% -1.29% 2.54% 1.13% 7.24% 20.15%
Profitability Metrics
- - - - - - - - - -
Gross Margin
81.58% 81.87% 80.95% 81.71% 80.38% 81.56% 80.19% 80.25% 80.14% 80.74%
EBITDA Margin
-32.63% -5.29% -30.68% -29.20% -40.60% -8.54% -33.50% -43.78% -29.16% 2.17%
Operating Margin
-34.24% -7.03% -32.65% -31.11% -43.72% -10.90% -37.11% -48.10% -33.57% -0.30%
EBIT Margin
-34.24% -7.03% -32.35% -31.11% -43.72% -10.90% -36.73% -47.92% -33.59% -0.87%
Profit (Net Income) Margin
-36.71% -8.87% -31.89% -29.25% -42.99% -10.10% -36.54% -47.70% -34.07% -0.73%
Tax Burden Percent
100.37% 54.30% 100.00% 99.23% 99.87% 96.56% 100.67% 99.85% 99.81% 49.60%
Interest Burden Percent
106.80% 232.34% 98.58% 94.74% 98.46% 95.92% 98.84% 99.70% 101.62% 169.75%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-138.22% -28.71% -121.01% -84.49% -112.63% -28.63% -92.37% -100.07% -66.22% -0.55%
ROIC Less NNEP Spread (ROIC-NNEP)
-130.97% -24.97% -116.91% -79.86% -103.02% -25.53% -86.16% -90.36% -56.57% 0.22%
Return on Net Nonoperating Assets (RNNOA)
95.24% 17.07% 88.91% 48.85% 54.14% 12.70% 52.71% 44.31% 23.02% -0.08%
Return on Equity (ROE)
-42.98% -11.64% -32.10% -35.64% -58.48% -15.93% -39.67% -55.77% -43.20% -0.63%
Cash Return on Invested Capital (CROIC)
-160.44% -163.70% -175.67% -162.05% -160.22% -143.90% -123.89% -78.42% -69.87% -78.04%
Operating Return on Assets (OROA)
-29.23% -6.65% -25.34% -25.44% -38.49% -9.93% -29.27% -39.99% -30.06% -0.77%
Return on Assets (ROA)
-31.34% -8.39% -24.98% -23.92% -37.85% -9.19% -29.13% -39.81% -30.49% -0.65%
Return on Common Equity (ROCE)
-42.98% -11.64% -32.09% -35.64% -58.48% -15.93% -39.66% -55.77% -43.20% -0.63%
Return on Equity Simple (ROE_SIMPLE)
-72.38% 0.00% -29.97% -28.19% -34.57% 0.00% -43.32% -56.79% -58.65% 0.00%
Net Operating Profit after Tax (NOPAT)
-7.92 -2.45 -9.64 -9.14 -12 -4.75 -13 -15 -11 -0.14
NOPAT Margin
-23.97% -4.92% -22.85% -21.78% -30.60% -7.63% -25.98% -33.67% -23.50% -0.21%
Net Nonoperating Expense Percent (NNEP)
-7.26% -3.74% -4.10% -4.62% -9.60% -3.11% -6.21% -9.71% -9.65% -0.77%
Return On Investment Capital (ROIC_SIMPLE)
- -2.16% - - - -2.49% - - - -0.09%
Cost of Revenue to Revenue
18.42% 18.13% 19.05% 18.29% 19.62% 18.44% 19.81% 19.75% 19.86% 19.26%
SG&A Expenses to Revenue
26.97% 20.91% 25.75% 23.91% 31.13% 21.62% 28.10% 31.98% 30.00% 19.81%
R&D to Revenue
11.49% 7.53% 8.09% 8.40% 10.67% 6.67% 10.29% 11.60% 11.01% 7.58%
Operating Expenses to Revenue
115.82% 88.90% 113.60% 112.59% 124.04% 92.11% 117.15% 128.09% 113.66% 80.87%
Earnings before Interest and Taxes (EBIT)
-11 -3.50 -14 -13 -18 -6.78 -19 -21 -15 -0.60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-11 -2.63 -13 -12 -17 -5.31 -17 -19 -13 1.49
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
19.66 21.08 9.78 10.46 5.85 5.70 6.37 3.68 3.44 4.11
Price to Tangible Book Value (P/TBV)
19.66 21.08 9.78 12.29 6.97 6.77 7.68 4.54 4.31 5.04
Price to Revenue (P/Rev)
9.74 9.00 9.94 9.40 4.62 4.20 4.11 2.08 1.78 2.21
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
45.14 39.00 34.87 23.40 10.75 10.57 10.77 5.27 4.40 4.87
Enterprise Value to Revenue (EV/Rev)
9.46 8.79 9.18 8.88 4.22 3.83 3.82 1.87 1.63 2.11
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.85 0.87 0.33 0.35 0.38 0.38 0.42 0.47 0.51 0.47
Long-Term Debt to Equity
0.85 0.87 0.33 0.35 0.38 0.38 0.42 0.47 0.51 0.47
Financial Leverage
-0.73 -0.68 -0.76 -0.61 -0.53 -0.50 -0.61 -0.49 -0.41 -0.37
Leverage Ratio
1.84 1.95 1.62 1.84 1.98 2.07 1.73 1.82 1.87 1.87
Compound Leverage Factor
1.97 4.54 1.60 1.75 1.95 1.99 1.71 1.81 1.90 3.17
Debt to Total Capital
45.84% 46.55% 25.09% 26.06% 27.74% 27.76% 29.58% 32.16% 33.66% 32.07%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
45.84% 46.55% 25.09% 26.06% 27.74% 27.76% 29.58% 32.16% 33.66% 32.07%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
54.16% 53.45% 74.88% 73.94% 72.26% 72.24% 70.42% 67.84% 66.34% 67.93%
Debt to EBITDA
-1.49 -1.60 -1.39 -1.36 -1.19 -1.12 -1.03 -0.91 -0.96 -1.11
Net Debt to EBITDA
1.02 0.87 3.11 2.24 1.56 1.49 1.11 0.71 0.53 0.46
Long-Term Debt to EBITDA
-1.49 -1.60 -1.39 -1.36 -1.19 -1.12 -1.03 -0.91 -0.96 -1.11
Debt to NOPAT
-2.04 -2.16 -1.86 -1.81 -1.57 -1.47 -1.34 -1.17 -1.22 -1.37
Net Debt to NOPAT
1.39 1.17 4.16 2.97 2.05 1.95 1.44 0.92 0.68 0.57
Long-Term Debt to NOPAT
-2.04 -2.16 -1.86 -1.81 -1.57 -1.47 -1.34 -1.17 -1.22 -1.37
Altman Z-Score
8.44 8.62 10.95 10.13 5.23 4.78 4.52 2.34 2.15 3.10
Noncontrolling Interest Sharing Ratio
0.00% 0.03% 0.04% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
5.66 4.41 9.58 6.60 5.64 4.40 3.98 3.86 4.12 4.62
Quick Ratio
4.74 3.65 8.41 5.55 4.44 3.58 2.98 2.71 2.80 3.34
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-17 -18 -33 -50 -55 -41 -42 -22 -17 -23
Operating Cash Flow to CapEx
-127.76% -229.76% -1,167.73% -197.00% -271.72% 23.67% -183.88% -803.76% -413.62% -136.86%
Free Cash Flow to Firm to Interest Expense
-14.27 -1.74 -25.44 -38.79 -42.29 -31.06 -31.85 -16.68 -13.18 -17.44
Operating Cash Flow to Interest Expense
-6.29 -0.52 -13.43 -6.50 -7.34 0.41 -5.48 -10.59 -9.02 -3.20
Operating Cash Flow Less CapEx to Interest Expense
-11.21 -0.75 -14.58 -9.80 -10.04 -1.32 -8.46 -11.91 -11.20 -5.54
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.85 0.95 0.78 0.82 0.88 0.91 0.80 0.83 0.90 0.89
Accounts Receivable Turnover
8.27 5.94 7.49 7.64 8.02 5.56 7.07 7.52 8.25 5.31
Inventory Turnover
1.61 1.71 1.69 1.57 1.42 1.45 1.28 1.14 1.08 1.20
Fixed Asset Turnover
15.33 15.60 15.57 11.85 9.79 9.94 9.70 9.09 8.69 8.68
Accounts Payable Turnover
4.24 4.01 6.67 5.48 3.95 3.43 2.84 2.93 2.88 3.68
Days Sales Outstanding (DSO)
44.12 61.46 48.70 47.80 45.49 65.60 51.62 48.53 44.24 68.75
Days Inventory Outstanding (DIO)
226.42 213.66 215.80 232.49 257.06 251.98 285.87 320.44 338.37 304.22
Days Payable Outstanding (DPO)
86.10 90.95 54.70 66.58 92.33 106.36 128.42 124.69 126.81 99.29
Cash Conversion Cycle (CCC)
184.43 184.16 209.81 213.72 210.22 211.22 209.07 244.28 255.80 273.68
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
26 32 41 63 69 68 69 70 75 91
Invested Capital Turnover
5.77 5.84 5.29 3.88 3.68 3.75 3.56 2.97 2.82 2.65
Increase / (Decrease) in Invested Capital
9.06 15 23 41 42 36 29 6.91 6.71 23
Enterprise Value (EV)
1,187 1,247 1,423 1,482 738 716 748 370 331 441
Market Capitalization
1,223 1,276 1,541 1,569 807 786 805 412 361 463
Book Value per Share
$1.12 $1.09 $2.58 $2.45 $2.24 $2.24 $2.05 $1.81 $1.69 $1.81
Tangible Book Value per Share
$1.12 $1.09 $2.58 $2.08 $1.88 $1.88 $1.70 $1.46 $1.35 $1.48
Total Capital
115 113 210 203 191 191 179 165 158 166
Total Debt
53 53 53 53 53 53 53 53 53 53
Total Long-Term Debt
53 53 53 53 53 53 53 53 53 53
Net Debt
-36 -29 -118 -87 -69 -70 -57 -42 -30 -22
Capital Expenditures (CapEx)
5.86 2.33 1.48 4.23 3.50 2.25 3.93 1.73 2.86 3.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)
17 22 29 29 32 30 30 32 37 51
Debt-free Net Working Capital (DFNWC)
105 103 200 168 154 153 140 127 119 126
Net Working Capital (NWC)
105 103 200 168 154 153 140 127 119 126
Net Nonoperating Expense (NNE)
4.21 1.96 3.81 3.13 5.05 1.53 5.40 6.24 4.77 0.36
Net Nonoperating Obligations (NNO)
-36 -29 -117 -87 -69 -70 -57 -42 -30 -22
Total Depreciation and Amortization (D&A)
0.53 0.87 0.70 0.80 1.27 1.47 1.65 1.84 2.00 2.09
Debt-free, Cash-free Net Working Capital to Revenue
13.37% 15.44% 18.82% 17.13% 18.22% 16.10% 15.48% 16.15% 18.01% 24.26%
Debt-free Net Working Capital to Revenue
83.92% 72.73% 128.94% 100.66% 88.16% 81.94% 71.59% 64.02% 58.83% 60.41%
Net Working Capital to Revenue
83.92% 72.73% 128.94% 100.66% 88.16% 81.94% 71.59% 64.02% 58.83% 60.41%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.22) ($0.08) ($0.23) ($0.20) ($0.28) ($0.10) ($0.30) ($0.34) ($0.25) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding
55.43M 55.28M 58.72M 61.38M 61.56M 60.85M 61.79M 62.08M 62.23M 62.11M
Adjusted Diluted Earnings per Share
($0.22) ($0.08) ($0.23) ($0.20) ($0.28) ($0.10) ($0.30) ($0.34) ($0.25) ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding
55.43M 55.28M 58.72M 61.38M 61.56M 60.85M 61.79M 62.08M 62.23M 62.11M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
55.50M 61.16M 61.33M 61.54M 61.68M 61.76M 62.01M 62.19M 62.30M 62.62M
Normalized Net Operating Profit after Tax (NOPAT)
-7.92 -2.45 -9.64 -9.14 -12 -4.75 -13 -15 -11 -0.14
Normalized NOPAT Margin
-23.97% -4.92% -22.85% -21.78% -30.60% -7.63% -25.98% -33.67% -23.50% -0.21%
Pre Tax Income Margin
-36.57% -16.33% -31.89% -29.48% -43.04% -10.46% -36.30% -47.77% -34.13% -1.47%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-9.51 -0.34 -10.62 -10.18 -13.75 -5.20 -14.25 -16.24 -11.53 -0.45
NOPAT to Interest Expense
-6.66 -0.24 -7.50 -7.13 -9.62 -3.64 -10.08 -11.41 -8.07 -0.11
EBIT Less CapEx to Interest Expense
-14.43 -0.57 -11.77 -13.48 -16.45 -6.92 -17.23 -17.55 -13.71 -2.79
NOPAT Less CapEx to Interest Expense
-11.58 -0.47 -8.65 -10.43 -12.33 -5.36 -13.06 -12.73 -10.25 -2.45
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Treace Medical Concepts' Financials

When does Treace Medical Concepts's financial year end?

According to the most recent income statement we have on file, Treace Medical Concepts' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Treace Medical Concepts' net income changed over the last 2 years?

Treace Medical Concepts' net income appears to be on an upward trend, with a most recent value of -$55.74 million in 2024, rising from -$42.82 million in 2022. The previous period was -$49.53 million in 2023.

What is Treace Medical Concepts's operating income?
Treace Medical Concepts's total operating income in 2024 was -$55.69 million, based on the following breakdown:
  • Total Gross Profit: $168.26 million
  • Total Operating Expenses: $223.63 million
How has Treace Medical Concepts revenue changed over the last 2 years?

Over the last 2 years, Treace Medical Concepts' total revenue changed from $141.84 million in 2022 to $209.36 million in 2024, a change of 47.6%.

How much debt does Treace Medical Concepts have?

Treace Medical Concepts' total liabilities were at $104.20 million at the end of 2024, a 8.6% decrease from 2023, and a 5.8% increase since 2022.

How much cash does Treace Medical Concepts have?

In the past 2 years, Treace Medical Concepts' cash and equivalents has ranged from $11.35 million in 2024 to $19.47 million in 2022, and is currently $11.35 million as of their latest financial filing in 2024.

How has Treace Medical Concepts' book value per share changed over the last 2 years?

Over the last 2 years, Treace Medical Concepts' book value per share changed from 1.09 in 2022 to 1.81 in 2024, a change of 66.2%.



This page (NASDAQ:TMCI) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners